Testicular Cancer

P1, N=26, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jul 2026 --> Jun 2025

P=N/A, N=80, Recruiting, Loma Linda University | Initiation date: Dec 2025 --> May 2026

P=N/A, N=1000, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028

This case shows that monitoring of etoposide plasma concentrations can be beneficial in complex clinical scenarios involving organ dysfunction and/or potential drug-drug interactions. This is especially important in curative treatment to avoid under dosing. This case report highlights the challenges of dosing etoposide in a patient with cystic fibrosis and liver cirrhosis who is taking multiple drugs that may interact with etoposide. The patient should be monitored closely on how the treatment is tolerated and the dose should be adjusted accordingly.

While first-line BEP (bleomycin, etoposide, cisplatin) chemotherapy achieves high cure rates in most patients, those who progress after multiple lines of therapy have a poor prognosis and limited treatment options, highlighting a critical gap in effective treatment decision-making for advanced disease...He then experienced rapid progression with new lung and brain metastases that were unresponsive to second-line GEMOX (gemcitabine + oxaliplatin) chemotherapy and a programmed death-ligand 1 (PD-L1) blockade clinical trial...Guided by a molecular tumor board (MTB) recommendation, an off-label regimen of carboplatin, paclitaxel, and sorafenib (CPS) was initiated, targeting the MAPK pathway...Tumors are highly complex, and gene-cancer interaction is still being elucidated. In this context, key learning points from this case include: 1) the critical role of iterative molecular profiling and MTB guidance in identifying actionable targets when standard options are exhausted; 2) the potential value of rational drug rechallenge informed by the evolving "tumor ecology;" and 3) the necessity of long-term follow-up to link treatment responses with biomarkers, allowing N-of-1 learning that may offer a template for personalized management in similarly challenging cases.

He was treated with nine cycles of VDC-IE(vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) chemotherapy given at 3-week intervals, complicated by transient iron deficiency anaemia, followed by surgical excision with neck dissection and fibular flap reconstruction. Maintenance therapy with the histone deacetylase inhibitor vorinostat was initiated. This case highlights the importance of early recognition, multimodal therapy and emerging targeted treatment in improving outcomes for NUT carcinoma.

Primary uterine NUT carcinoma may be misdiagnosed as other undifferentiated uterine tumors due to its rarity and histological overlap. Given the diagnostic challenges, NUT IHC staining and molecular testing for NUTM1 rearrangement should be considered in undifferentiated uterine tumors with ambiguous histopathological features.

P1, N=44, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Feb 2030 --> Jan 2031 | Trial primary completion date: Feb 2030 --> Jan 2031

The patient underwent systemic chemotherapy rechallenge and palliative radiotherapy. This case illustrates the diagnostic challenges of testicular metastasis in advanced SCLC, highlights the sanctuary-site concept, and emphasizes the importance of clinical context when histologic confirmation is not feasible.

Architecturally more complex forms within this spectrum exist and have been labelled as having "uncertain malignant potential." Malignant mesothelioma of the tunica vaginalis is an uncommon but aggressive tumor that may show loss of BAP1 or MTAP immunostaining, supporting a distinct molecular pathogenesis. This review summarizes the clinicopathologic, immunohistochemically, and molecular features of mesothelial lesions of the paratestis, emphasizing their morphologic overlap, diagnostic pitfalls, and evolving framework for classification.

P2, N=68, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting